Novavax Makes One Million Doses of Nuvaxovid™ Available for Use in the United Kingdom

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that an initial one million doses of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine are now available for use in the United Kingdom (U.K.). Nuvaxovid is the first protein-based COVID-19 vaccine granted authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) and will be offered per the Joint Committee on Vaccination and Immunisation (JCVI) advice.

“With U.K. data showing that people infected with both COVID-19 and the flu are more than five times as likely to die compared to someone with no infection¹, it is more important than ever to consider any vaccine offered to you by the National Health Service,” said Stanley C. Erck, President and Chief Executive Officer, Novavax. “We continue to believe in the importance of a diversified national vaccine portfolio to reduce winter pressures on the health service.”

Nuvaxovid was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike protein and is formulated with Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the immune response. Nuvaxovid contains purified protein antigen and can neither replicate, nor can it cause COVID-19.

The MHRA granted Conditional Marketing Authorization (CMA) for Nuvaxovid’s use as a two-dose primary series vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults aged 18 and older in February 2022, and in adolescents aged 12 through 17 in August 2022. Novavax submitted a request to the MHRA for expanded CMA of Nuvaxovid as a booster in adults aged 18 and older on June 1, 2022 and is awaiting a decision from the agency.